199 related articles for article (PubMed ID: 11684550)
21. Comparison of citrate anticoagulation during plasma exchange with different replacement solutions.
Antonic M; Gubensek J; Buturović-Ponikvar J; Ponikvar R
Ther Apher Dial; 2009 Aug; 13(4):322-6. PubMed ID: 19695068
[TBL] [Abstract][Full Text] [Related]
22. Citrate anticoagulation and dialysate with reduced buffer content in chronic hemodialysis.
van der Meulen J; Janssen MJ; Langendijk PN; Bouman AA; Oe PL
Clin Nephrol; 1992 Jan; 37(1):36-41. PubMed ID: 1541063
[TBL] [Abstract][Full Text] [Related]
23. Citrate anticoagulation for single-needle hemodialysis: safety and efficacy.
Buturović-Ponikvar J; Gubensek J; Ponikvar R
Ther Apher Dial; 2005 Jun; 9(3):237-40. PubMed ID: 15966997
[TBL] [Abstract][Full Text] [Related]
24. Citrate haemodialysis.
Faber LM; de Vries PM; Oe PL; van der Meulen J; Donker AJ
Neth J Med; 1990 Dec; 37(5-6):219-24. PubMed ID: 2074914
[TBL] [Abstract][Full Text] [Related]
25. Citrate versus heparin anticoagulation in chronic haemodialysis patients.
Janssen MJ; Huijgens PC; Bouman AA; Oe PL; Donker AJ; van der Meulen J
Nephrol Dial Transplant; 1993; 8(11):1228-33. PubMed ID: 8302461
[TBL] [Abstract][Full Text] [Related]
26. Citrate clearance in children receiving continuous venovenous renal replacement therapy.
Chadha V; Garg U; Warady BA; Alon US
Pediatr Nephrol; 2002 Oct; 17(10):819-24. PubMed ID: 12376810
[TBL] [Abstract][Full Text] [Related]
27. Citrate anticoagulation during plasma exchange in a patient with thrombotic thrombocytopenic purpura: short heparin-free hemodialysis helps to attenuate citrate load.
Buturović-Ponikvar J; Pernat AM; Ponikvar R
Ther Apher Dial; 2005 Jun; 9(3):258-61. PubMed ID: 15967002
[TBL] [Abstract][Full Text] [Related]
28. Safety of regional citrate anticoagulation for continuous sustained low efficiency dialysis (C-SLED) in critically ill patients.
Finkel KW; Foringer JR
Ren Fail; 2005; 27(5):541-5. PubMed ID: 16152991
[TBL] [Abstract][Full Text] [Related]
29. Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding.
Pinnick RV; Wiegmann TB; Diederich DA
N Engl J Med; 1983 Feb; 308(5):258-61. PubMed ID: 6848936
[No Abstract] [Full Text] [Related]
30. [Factors which influence phosphorus removal in hemodialysis].
Gallar P; Ortiz M; Ortega O; Rodríguez I; Seijas V; Carreño A; Oliet A; Vigil A
Nefrologia; 2007; 27(1):46-52. PubMed ID: 17402879
[TBL] [Abstract][Full Text] [Related]
31. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
Frank RD; Brandenburg VM; Lanzmich R; Floege J
Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
[TBL] [Abstract][Full Text] [Related]
32. Effect of anticoagulation on blood membrane interactions during hemodialysis.
Hofbauer R; Moser D; Frass M; Oberbauer R; Kaye AD; Wagner O; Kapiotis S; Druml W
Kidney Int; 1999 Oct; 56(4):1578-83. PubMed ID: 10504511
[TBL] [Abstract][Full Text] [Related]
33. Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study.
Naumnik B; Rydzewska-Rosołowska A; Myśliwiec M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):480-6. PubMed ID: 20682597
[TBL] [Abstract][Full Text] [Related]
34. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience.
Morgera S; Scholle C; Voss G; Haase M; Vargas-Hein O; Krausch D; Melzer C; Rosseau S; Zuckermann-Becker H; Neumayer HH
Nephron Clin Pract; 2004; 97(4):c131-6. PubMed ID: 15331942
[TBL] [Abstract][Full Text] [Related]
35. Use of regional citrate anticoagulation with medium cut-off membrane: pilot report.
Vrečko MM; Pajek J; Buturović-Ponikvar J
BMC Nephrol; 2022 Oct; 23(1):346. PubMed ID: 36303108
[TBL] [Abstract][Full Text] [Related]
36. Regional Citrate Anticoagulation for Intermittent Hemodialysis in Dogs.
Francey T; Schweighauser A
J Vet Intern Med; 2018 Jan; 32(1):147-156. PubMed ID: 29171099
[TBL] [Abstract][Full Text] [Related]
37. Effects of efficiency and length of acetate-free biofiltration session on postdialysis solute rebound.
Giannattasio P; Minutolo R; Bellizzi V; Di Iorio BR; Scigliano R; Zamboli P; Venditti G; Manganelli R; De Simone W; Aucella F; Stallone C; Spiezia S; Conte G; De Nicola L
Am J Kidney Dis; 2006 Jun; 47(6):1045-54. PubMed ID: 16731300
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of regional citrate anticoagulation in liver transplant patients requiring post-operative renal replacement therapy.
Saner FH; Treckmann JW; Geis A; Lösch C; Witzke O; Canbay A; Herget-Rosenthal S; Kribben A; Paul A; Feldkamp T
Nephrol Dial Transplant; 2012 Apr; 27(4):1651-7. PubMed ID: 22049184
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of three different methods to prevent dialyzer clotting without causing systemic anticoagulation effect.
Richtrova P; Rulcova K; Mares J; Reischig T
Artif Organs; 2011 Jan; 35(1):83-8. PubMed ID: 20626736
[TBL] [Abstract][Full Text] [Related]
40. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
Bechtold H; Gunzenhauser D; Sawitzki H; Fung S; Janssen D
Z Kardiol; 2003 Jul; 92(7):532-9. PubMed ID: 12883837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
